Literature DB >> 1955724

Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA.

E Fikrig1, S W Barthold, F S Kantor, R A Flavell.   

Abstract

Mice immunized with recombinant outer surface protein A (OspA) in Freund's adjuvant or with intraperitoneal injections of live Escherichia coli expressing OspA have been shown to be protected from infection with Borrelia burgdorferi. To investigate the efficacy of oral vaccination, C3H/He mice were inoculated with 10(8) live E. coli expressing recombinant OspA by gavage and boosted in a similar manner on days 10, 20, 30, and 40. The animals developed serum IgG antibodies to OspA by immunoblot and were protected from infection when challenged with 10(4) B. burgdorferi intradermally 14 days after the last boost. Control mice did not develop antibodies to OspA and were not protected against challenge infection. These results suggest that an oral preparation of recombinant OspA could potentially be used for vaccination.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955724     DOI: 10.1093/infdis/164.6.1224

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease.

Authors:  Debaditya Bhattacharya; Mekki Bensaci; Kathryn E Luker; Gary Luker; Steven Wisdom; Sam R Telford; Linden T Hu
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

2.  Structural basis for complement evasion by Lyme disease pathogen Borrelia burgdorferi.

Authors:  Arnab Bhattacharjee; Jesper S Oeemig; Robert Kolodziejczyk; Taru Meri; Tommi Kajander; Markus J Lehtinen; Hideo Iwaï; T Sakari Jokiranta; Adrian Goldman
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

Review 3.  Lyme disease vaccine.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

Review 4.  Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.

Authors:  A Sadziene; A G Barbour
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

5.  Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.

Authors:  Luciana Meirelles Richer; Miguel Aroso; Tania Contente-Cuomo; Larisa Ivanova; Maria Gomes-Solecki
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

6.  Access of antibody or trypsin to an integral outer membrane protein (P66) of Borrelia burgdorferi is hindered by Osp lipoproteins.

Authors:  J Bunikis; A G Barbour
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Reservoir targeted vaccine against Borrelia burgdorferi: a new strategy to prevent Lyme disease transmission.

Authors:  Luciana Meirelles Richer; Dustin Brisson; Rita Melo; Richard S Ostfeld; Nordin Zeidner; Maria Gomes-Solecki
Journal:  J Infect Dis       Date:  2014-02-11       Impact factor: 5.226

8.  Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Authors:  Y F Chang; M J Appel; R H Jacobson; S J Shin; P Harpending; R Straubinger; L A Patrican; H Mohammed; B A Summers
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Reductions in human Lyme disease risk due to the effects of oral vaccination on tick-to-mouse and mouse-to-tick transmission.

Authors:  Maarten J Voordouw; Haley Tupper; Özlem Önder; Godefroy Devevey; Christopher J Graves; Brian D Kemps; Dustin Brisson
Journal:  Vector Borne Zoonotic Dis       Date:  2013-02-21       Impact factor: 2.133

10.  Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.

Authors:  M Dunne; B K al-Ramadi; S W Barthold; R A Flavell; E Fikrig
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.